Cargando…
Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study
BACKGROUND: The incidence of multi-drug resistant ESBL-associated urinary tract infections (UTIs) is increasing globally. Patients with abnormal renal tract anatomy and other co-morbidities are at increased risk of complicated UTI and ESBL-associated infections. The duration and safety of OPAT for t...
Autores principales: | Fink, Doug L., Collins, Steven, Barret, Ronnie, Pollara, Gabriele, Marks, Michael, Logan, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762133/ https://www.ncbi.nlm.nih.gov/pubmed/31557236 http://dx.doi.org/10.1371/journal.pone.0223130 |
Ejemplares similares
-
Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy
por: Underwood, Jonathan, et al.
Publicado: (2019) -
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy
por: Marks, Michael, et al.
Publicado: (2020) -
Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration
por: Britt, Rachel S, et al.
Publicado: (2019) -
1923. OPAT or No-PAT? Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Daptomycin or Ertapenem for “Ease of Administration”
por: Britt, Rachel S, et al.
Publicado: (2018) -
Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections
por: Wong, Carrie P., et al.
Publicado: (2021)